Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Non-Current Assets (2018 - 2025)

Historic Non-Current Assets for Bicycle Therapeutics (BCYC) over the last 8 years, with Q3 2025 value amounting to $11.4 million.

  • Bicycle Therapeutics' Non-Current Assets fell 4458.08% to $11.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.4 million, marking a year-over-year decrease of 4458.08%. This contributed to the annual value of $17.2 million for FY2024, which is 3791.0% down from last year.
  • As of Q3 2025, Bicycle Therapeutics' Non-Current Assets stood at $11.4 million, which was down 4458.08% from $14.1 million recorded in Q2 2025.
  • Bicycle Therapeutics' Non-Current Assets' 5-year high stood at $37.0 million during Q1 2023, with a 5-year trough of $5.7 million in Q3 2021.
  • Moreover, its 5-year median value for Non-Current Assets was $22.5 million (2024), whereas its average is $21.6 million.
  • Per our database at Business Quant, Bicycle Therapeutics' Non-Current Assets soared by 44227.17% in 2022 and then crashed by 4458.08% in 2025.
  • Bicycle Therapeutics' Non-Current Assets (Quarter) stood at $17.8 million in 2021, then soared by 84.2% to $32.8 million in 2022, then fell by 15.52% to $27.7 million in 2023, then crashed by 37.91% to $17.2 million in 2024, then crashed by 33.54% to $11.4 million in 2025.
  • Its last three reported values are $11.4 million in Q3 2025, $14.1 million for Q2 2025, and $15.4 million during Q1 2025.